Key Highlights

  • Digital Currency X Technology fell 22.2%, with a 94.8% monthly drop that warrants a data check.
  • Ocular Therapeutix dropped 19.8% and is down 29.4% over the month.
  • Boeing's common shares fell 6.3%, while its convertible preferred depositary shares lost 5.0%.
  • Only VEON and Target Hospitality are higher over the month.

The final group of today's large-cap decliners covers a wide mix of businesses, from aircraft makers and autonomous trucking to eye care, education and leisure. Twenty stocks with market caps above USD 1 billion fell 5% or more. Without a single sector theme, the moves are best read one stock at a time.

Steepest Declines

Digital Currency X Technology (NASDAQ:DCX) fell 22.2% to $6.15. The Chinese vehicle maker is down 72.8% for the week and down 94.8% for the month. A 94.8% monthly fall is extreme, so these figures are worth checking against exchange records.

Ocular Therapeutix (NASDAQ:OCUL) dropped 19.8% to $7.74. The eye disease drug developer is down 23.2% for the week and down 29.4% for the month.

Aurora Innovation (NASDAQ:AUR) declined 11.7% to $5.33. The self-driving truck technology company is down 18.4% for the week and down 6.5% for the month.

Seaport Therapeutics (NASDAQ:SPTX) slipped 7.8% to $19.84. The neuropsychiatric drug developer is down 7.5% for the week and down 23.9% for the month.

Universal Technical Institute (NYSE:UTI) lost 7.7% to $18.74. The technical Training school operator is down 7.9% for the week and down 14.0% for the month.

Archer Aviation (NYSE:ACHR) fell 7.2% to $5.21. The electric air taxi developer is down 3.1% for the week and down 11.5% for the month.

Afya (NASDAQ:AFYA) dropped 7.0% to $12.09. The Brazilian medical education company is down 11.5% for the week and down 15.9% for the month.

Telecom Argentina (NYSE:TEO) declined 7.0% to $12.12. The Argentine telecom operator is down 12.1% for the week and down 7.2% for the month.

AIR Global (NASDAQ:AIIR) slipped 6.8% to $7.10. The hookah and inhalation products maker is up 1.7% for the week and down 20.8% for the month.

Warby Parker (NYSE:WRBY) lost 6.7% to $24.92. The eyewear retailer is up 9.0% for the week and down 1.3% for the month.

Other Decliners in the Group

ADI Global Distribution (NYSE:ADIG) fell 6.6% to $18.25. The low-voltage products distributor is down 13.4% for the week and down 17.4% for the month.

Viking Therapeutics (NASDAQ:VKTX) dropped 6.6% to $33.21. The metabolic disease drug developer is up 12.3% for the week and down 1.6% for the month.

Target Hospitality (NASDAQ:TH) declined 6.5% to $19.25. The workforce lodging provider is down 11.1% for the week and up 1.3% for the month.

Boeing (NYSE:BA) slipped 6.3% to $185.54. The aircraft maker is down 7.4% for the week and down 11.6% for the month.

VEON (NASDAQ:VEON) lost 6.1% to $69.00. The telecom and digital services group is down 0.8% for the week and up 15.0% for the month.

ERock (NYSE:EROC) fell 6.0% to $11.85. The distributed power systems company is down 11.9% for the week and down 9.5% for the month.

Churchill Downs (NASDAQ:CHDN) dropped 5.8% to $75.14. The racing and gaming company is down 8.6% for the week and down 13.6% for the month.

Six Flags Entertainment (NYSE:FUN) declined 5.6% to $11.63. The amusement park operator is down 5.7% for the week and down 26.7% for the month.

Harrow (NASDAQ:HROW) slipped 5.1% to $31.38. The eye care pharmaceutical company is down 5.5% for the week and down 18.5% for the month.

Boeing 6.00% Series A mandatory convertible preferred depositary shares (NYSE:BA/PA) lost 5.0% to $58.73. The instrument is down 7.3% for the week and down 9.7% for the month, tracking a softer move than the common shares.

Reading a Mixed Group

With such a varied list, no single Factor explains today's declines. The largest moves, in Digital currency X Technology and Ocular Therapeutix, stand apart from the rest and deserve a check against company filings. For most other names, today's drop extends modest monthly declines.

Disclaimer: This article is for general information only and does not constitute Investment advice. Readers should do their own research before investing.